European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition Faecal occult blood testing

Endoscopy

Volumn 44, Issue SUPPL3, 2012, Pages

  Halloran, S P ^a   Launoy, G ^b   Zappa, M ^c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITÉ DE CAEN   (France)

^c ISPO Cancer Prevention and Research Institute   (Italy)

Author keywords

colorectal neoplasms; laboratory quality control; mass screening; multidisciplinary evidence based guidelines; population based programmes; quality assessment; stool test

Indexed keywords

ALBUMIN; ANTIGEN; ATAXIN 3; BENZIDINE; CALGRANULIN; COLON SPECIFIC ANTIGEN 3; COLON SPECIFIC ANTIGEN 4; DESIPRAMINE; DNA; GUAIAC; HAPTOGLOBIN; HEMOGLOBIN; IMIPRAMINE; PYRUVATE KINASE; TOLUIDINE DERIVATIVE; TRANSFERRIN; UNCLASSIFIED DRUG;

CANCER CONTROL; CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIET RESTRICTION; EUROPE; EVIDENCE BASED PRACTICE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MEDICAL SOCIETY; OCCULT BLOOD TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; SAMPLING; STANDARD;

ALGORITHMS; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; EUROPEAN UNION; FECES; GUAIAC; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; INDICATORS AND REAGENTS; MASS SCREENING; OCCULT BLOOD; PATIENT COMPLIANCE; QUALITY ASSURANCE, HEALTH CARE; SENSITIVITY AND SPECIFICITY;

EID: 84866527934     PISSN: 0013726X     EISSN: 14388812     Source Type: Journal    
DOI: 10.1055/s-0032-1309791     Document Type: Review

References (137)

1. Achord J. L. Positive Hemoccult reactions after oral iron: true or false? Gastroenterology: 1983; 84 670 672
2. Ahlquist D. A., McGill D. B., Schwartz S. et al. HemoQuant, a new quantitative assay for fecal hemoglobin. Comparison with Hemoccult. Ann Intern Med: 1984; 101 297 302 (Pubitemid 14033774)
3. Ahlquist D. A., McGill D. B., Schwartz S. et al. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med: 1985; 312 1422 1428 (Pubitemid 15083660)
4. Allison J. E., Sakoda L. C., Levin T. R. et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst: 2007; 99 1462 1470
5. Allison J. E., Tekawa I. S., Ransom L. J. et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med: 1996; 334 155 159 (Pubitemid 26017953)
6. Anderson G. D., Yuellig T. R., Krone R. E. et al. An investigation into the effects of oral iron supplementation on in vivo Hemoccult stool testing. Am J Gastroenterol: 1990; 85 558 561 (Pubitemid 20164313)
7. Atkin W., Valori R., Kuipers E. J. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Colonoscopic surveillance following adenoma removal. Endoscopy: 2012; 44 SE151 SE163
8. Austoker J., Giordano L., Hewitson P. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Communication. Endoscopy: 2012; 44 SE106 SE115
9. Screening Retest Fact Sheet. Australian Government DOHAA: 2009; http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/ bw-retest Accessed 11/2/2012
10. Australian Health Technology Advisory Committee (AHTAC) Colorectal Cancer Screening. Canberra Commonwealth Department of Health and Family Services: 1997
11. Bennitt W., Burtonwood C., Halloran S. Four faecal occult blood test kits. [monograph on the Internet]. London (UK) NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing: 2006; Report No. 05110. http://nhscep.useconnect.co.uk/CEPProducts/catalogue.aspx [Accessed 4/07/2012]
12. Bini E. J., Rajapaksa R. C., Weinshel E. H. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol: 2005; 100 1586 1592 (Pubitemid 41032368)
13. Burch J. A., Soares-Weiser K., St John D. J. et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen: 2007; 14 132 137 (Pubitemid 47511122)
14. Castiglione G., Grazzini G., Miccinesi G. et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen: 2002; 9 99 103 (Pubitemid 35205230)
15. Castiglione G., Visioli C. B., Ciatto S. et al. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme. Br J Cancer: 2007; 96 1750 1754 (Pubitemid 46847191)
16. Castiglione G., Zappa M., Grazzini G. et al. Screening for colorectal cancer by faecal occult blood test: comparison of immunochemical tests. J Med Screen: 2000; 7 35 37 (Pubitemid 30305465)
17. Chen L. S., Liao C. S., Chang S. H. et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen: 2007; 14 191 199
18. Chen W. D., Han Z. J., Skoletsky J. et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst: 2005; 97 1124 1132 (Pubitemid 41511211)
19. Cheng T. I., Wong J. M., Hong C. F. et al. Colorectal cancer screening in asymptomaic adults: comparison of colonoscopy, sigmoidoscopy and fecal occult blood tests. J Formos Med Assoc: 2002; 101 685 690
20. Ciatto S., Martinelli F., Castiglione G. et al. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme. Br J Cancer: 2007; 96 218 221 (Pubitemid 46160624)
21. Clarke P., Jack F., Carey F. A. et al. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis: 2006; 8 389 392 (Pubitemid 43676653)
22. Cole S. R., Young G. P. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust: 2001; 175 195 198 (Pubitemid 32791339)
23. Cole S. R., Young G. P., Esterman A. et al. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen: 2003; 10 117 122 (Pubitemid 38296846)
24. Conseil d'Évaluation des Technologies de la Santé du Quebec Colorectal cancer screening. Montreal Conseil d'Évaluation des Technologies de la Santé du Quebec: 2000
25. Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC). Off J Eur Union: 2003; 34 38
26. Craven O. Screening for colorectal cancer using the faecal occult blood test: a critical literature review. Eur J Oncol Nurs: 2001; 5 234 243
27. Dancourt V., Lejeune C., Lepage C. et al. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer: 2008; 44 2254 2258
28. Day N. E. Estimating the sensitivity of a screening test. J Epidemiol Community Health: 1985; 39 364 366 (Pubitemid 16211334)
29. Ellis R. J., Wilson S., Holder R. L. et al. Different faecal sampling methods alter the acceptability of faecal occult blood testing: a cross sectional community survey. Eur J Cancer: 2007; 43 1437 1444 (Pubitemid 46874067)
30. Faure H., Exbrayat C., Winckel P. et al. Moisture content of Hemoccult slides influences test sensitivity. Eur J Gastroenterol Hepatol: 2003; 15 1111 1114 (Pubitemid 37267227)
31. Federici A., Giorgi R. P., Borgia P. et al. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen: 2005; 12 83 88 (Pubitemid 40835139)
32. Fenocchi E., Martinez L., Tolve J. et al. Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test. Eur J Cancer Prev: 2006; 15 384 390 (Pubitemid 44252909)
33. Ferlay J., Shin H. R., Bray F. et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France International Agency for Research on Cancer: 2010; Available from: http://globocan.iarc.fr Accessed on 05/04/2012
34. Fludger S., Turner A. M., Harvey R. F. et al. Controlled prospective study of faecal occult blood screening for colorectal cancer in Bury, black pudding capital of the world. BMJ: 2002; 325 1444 1445 (Pubitemid 36026788)
35. Fraser C. G. Faecal occult blood tests eliminate, enhance or update? Ann Clin Biochem: 2008; 45 117 121 (Pubitemid 351724580)
36. Fraser C. G., Mathew C. M., McKay K. et al. Automated immunochemical quantitation of haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut: 2008; 57 1256 1260
37. Fraser C. G., Mathew C. M., Mowat N. A. et al. Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach. Gut: 2007; 56 1415 1418 (Pubitemid 47517837)
38. Fraser C. G., Matthew C. M., Mowat N. A. et al. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study. Lancet Oncol: 2006; 7 127 131 (Pubitemid 43159498)
39. Garrick D. P., Close J. R., McMurray W. Detection of occult blood in faeces. Lancet: 1977; 2 820 821
40. Grazzini G., Ventura L., Zappa M. et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut: 2010; 59 1511 1515
41. Grazzini G., Visioli C. B., Zorzi M. et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer: 2009; 100 259 265
42. Greenberg P. D., Bertario L., Gnauck R. et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol: 2000; 95 1331 1338 (Pubitemid 30263533)
43. Greenberg P. D., Cello J. P., Rockey D. C. Relationship of low-dose aspirin to GI injury and occult bleeding: a pilot study. Gastrointest Endosc: 1999; 50 618 622 (Pubitemid 29518041)
44. Greenwald B. A pilot study evaluating two alternate methods of stool collection for the fecal occult blood test. Medsurg Nurs: 2006; 15 89 94
45. Guittet L., Bouvier V., Mariotte N. et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut: 2007; 56 210 214
46. Guittet L., Bouvier V., Mariotte N. et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer: 2009; 100 1230 1235
47. Guittet L., Bouvier V., Mariotte N. et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer: 2009; 125 1127 1133
48. Hardcastle J. D., Chamberlain J. O., Robinson M. H. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet: 1996; 348 1472 1477 (Pubitemid 26400242)
49. Haug U., Brenner H. New stool tests for colorectal cancer screening: a systematic review focusing on performance characteristics and practicalness. Int J Cancer: 2005; 117 169 176 (Pubitemid 41377434)
50. Hewitson P., Glasziou P., Irwig L. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev: 2007; CD001216
51. Hol L., Wilschut J. A., van Ballegooijen M. et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer: 2009; 100 1103 1110
52. IARC Chemical Agents and Related Occupations. 2012;IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 100F.
53. Illingworth D. G. Influence of diet on occult blood tests. Gut: 1965; 6 595 598
54. Imafuku Y., Nagai T., Yoshida H. The effect of toilet sanitizers and detergents on immunological occult blood tests. Clin Chim Acta: 1996; 253 51 59 (Pubitemid 26281497)
55. Imperiale T. F. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med: 2007; 146 309 311 (Pubitemid 351650618)
56. Imperiale T. F., Ransohoff D. F., Itzkowitz S. H. et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med: 2004; 351 2704 2714 (Pubitemid 39665324)
57. Jaffe R. M., Kasten B., Young D. S. et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med: 1975; 83 824 826
58. Jaffe R. M., Zierdt W. A new occult blood test not subject to false-negative results from reducing substances. J Lab Clin Med: 1979; 93 879 886 (Pubitemid 10160715)
59. Kahi C. J., Imperiale T. F. Do aspirin and nonsteroidal anti-inflammatory drugs cause false-positive fecal occult blood test results? A prospective study in a cohort of veterans. Am J Med: 2004; 117 837 841 (Pubitemid 39602792)
60. Keong C. H. CITES as a tool in combatting illegal logging. International Forestry Review: 2009; 9 805 810
61. Kerr J., Day P., Broadstock M. et al. Systematic review of the effectiveness of population screening for colorectal cancer. N Z Med J: 2007; 120 U2629
62. Ko C. W., Dominitz J. A., Nguyen T. D. Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med: 2003; 115 111 114 (Pubitemid 37288838)
63. Kronborg O., Fenger C., Olsen J. et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet: 1996; 348 1467 1471 (Pubitemid 26400241)
64. Lamph S. A., Bennitt W. E., Brannon C. R. et al. Evaluation report: Immunochemical faecal occult blood tests. Guildford Centre for Evidence-based Purchasing: 2009; Report No. CEP09042. http://www.cancerscreening.nhs.uk/bowel/ ifobt.pdf [Accessed 28/07/2012]
65. Landsorp-Vogelaar I., von Karsa L. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Introduction. Endoscopy: 2012; 44 SE15 SE30
66. Launoy G., Berchi C. [Advantage of immunochemical fecal occult blood test in screening for colorectal cancer]. Bull Cancer: 2005; 92 885 890 (Pubitemid 41604957)
67. Launoy G. D., Bertrand H. J., Berchi C. et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer: 2005; 115 493 496 (Pubitemid 40663756)
68. Levi Z., Rozen P., Hazazi R. et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med: 2007; 146 244 255 (Pubitemid 351650610)
69. Levi Z., Rozen P., Hazazi R. et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol: 2009; 104 933 938
70. Levi Z., Rozen P., Hazazi R. et al. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer? Aliment Pharmacol Ther: 2006; 24 1475 1481 (Pubitemid 44657125)
71. Levin B., Hess K., Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med: 1997; 157 970 976 (Pubitemid 27190884)
72. Li C. M., Shiu M. N., Chia S. L. et al. Factors associated with referral compliance of abnormal immunochemical faecal occult blood test. J Med Screen: 2007; 14 186 190
73. Li S., Wang H., Hu J. et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer: 2006; 118 3078 3083
74. Lifton L. J., Kreiser J. False-positive stool occult blood tests caused by iron preparations. A controlled study and review of literature. Gastroenterology: 1982; 83 860 863 (Pubitemid 12060525)
75. Macrae F. A., St John D. J. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology: 1982; 82 891 898 (Pubitemid 12142534)
76. Malila N., Senore C., Armaroli P. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Organisation. Endoscopy: 2012; 44 SE31 SE48
77. Mandel J. S., Bond J. H., Church T. R. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med: 1993; 328 1365 1371 (Pubitemid 23131388)
78. Minozzi S., Armaroli P., Banzi R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Appendix 1: Systematic evidence review. 2010; http://bookshop.europa.eu/en/european- guidelines-for-quality-assurance-in-colorectal-cancer-screening-and-diagnosis- pbND3210390/ [Accessed 11/2/2012]
79. Minozzi S., Armaroli P., Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Principles of evidence assessment and methods for reaching recommendations. Endoscopy: 2012; 44 SE9 SE14
80. Moore R. A., Derry S., McQuay H. J. Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. Arthritis Res Ther: 2008; 10 R7
81. Morikawa T., Kato J., Yamaji Y. et al. Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas. Am J Gastroenterol: 2007; 102 2259 2264 (Pubitemid 47493843)
82. Morikawa T., Kato J., Yamaji Y. et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology: 2005; 129 422 428 (Pubitemid 41096630)
83. Moslein G., Schneider C., Theilmeier A. et al. [Analysis of the statistical value of various commercially available stool tests - a comparison of one stool sample in correlation to colonoscopy]. Dtsch Med Wochenschr: 2010; 135 557 562
84. Moss S., Ancelle-Park R., Brenner H. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Evaluation and interpretation of screening outcomes. Endoscopy: 2012; 44 SE49 SE64
85. Nakama H., Yamamoto M., Kamijo N. et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology: 1999; 46 228 231 (Pubitemid 29154752)
86. Nakama H., Zhang B., Fattah A. S. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer: 2000; 36 647 650 (Pubitemid 30156851)
87. Nakama H., Zhang B., Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer: 2001; 37 398 401 (Pubitemid 32182330)
88. Parekh M., Fendrick A. M., Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther: 2008; 27 697 712 (Pubitemid 351406306)
89. Pearson S., Bennitt W., Halloran S. Evaluation of eleven faecal occult blood test kits. London Medical Devices Agency: 2000; MDA/2000/05
90. Pignone M., Campbell M. K., Carr C. et al. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract: 2001; 4 150 156
91. Piper M. A. Immunochemical versus guaiac fecal occult blood tests. Chicago. IL, USA Blue Cross and Blue Shield Association, Technology Evaluation Center. TEC Assessment Programs: 2004; 19 (5)
92. Quirke P., Risio M., Lambert R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Quality assurance in pathology in colorectal cancer screening and diagnosis. Endoscopy: 2012; 44 SE116 SE130
93. Ransohoff D. F., Sandler R. S. Clinical practice. Screening for colorectal cancer. N Engl J Med: 2002; 346 40 44 (Pubitemid 34438919)
94. Rockey D. C., Koch J., Cello J. P. et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med: 1998; 339 153 159 (Pubitemid 28328479)
95. Rosenfield R. E., Kochwa S., Kaczera Z. et al. Nonuniform distribution of occult blood in feces. Am J Clin Pathol: 1979; 71 204 209 (Pubitemid 9131444)
96. Rozen P., Knaani J., Samuel Z. Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia. Dig Dis Sci: 1997; 42 2064 2071 (Pubitemid 27501991)
97. Rozen P., Knaani J., Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci: 1999; 44 756 760 (Pubitemid 29186321)
98. Rozen P., Knaani J., Samuel Z. Comparative screening with a sensitive guaiac and specific immunochemical occult blood test in an endoscopic study. Cancer: 2000; 89 46 52 (Pubitemid 30451272)
99. Rozen P., Waked A., Vilkin A. et al. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit: 2006; 12 MT27 MT32 (Pubitemid 43854430)
100. Rubeca T., Rapi S., Confortini M. et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening series 70. Int J Biol Markers: 2006; 21 157 161 (Pubitemid 44660287)
101. Said R. Contamination of urine with povidone-iodine. Cause of false-positive test for occult blood in urine. JAMA: 1979; 242 748 749 (Pubitemid 10243656)
102. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res: 1996; 87 1011 1024 (Pubitemid 26392036)
103. Saito H. Current status of colorectal cancer screening in Japan. Acta Endoscopica: 2007; 37 181 188 (Pubitemid 46713892)
104. Saito H., Soma Y., Nakajima M. et al. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test. Oncol Rep: 2000; 7 815 819
105. Schwartz M. K. How do we detect hereditary large bowel cancer? Biochemical diagnosis. Prog Clin Biol Res: 1983; 115 123 129
106. Scriven A. J., Tapley E. M. Coloscreen VPI test kit evaluated for detection of fecal occult blood. Clin Chem: 1989; 35 156 158 (Pubitemid 19046808)
107. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Segnan N., Patnick J., von Karsa L. Luxembourg European Commission, Publications Office of the European Union: 2010
108. Shastri Y. M., Naumann M., Oremek G. M. et al. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer: 2006; 119 2651 2656 (Pubitemid 44691321)
109. Sieg A., Thoms C., Luthgens K. et al. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int J Colorectal Dis: 1999; 14 267 271 (Pubitemid 30085258)
110. Sinatra M. A., St John D. J., Young G. P. Interference of plant peroxidases with guaiac-based fecal occult blood tests is avoidable. Clin Chem: 1999; 45 123 126 (Pubitemid 29036395)
111. Smith A., Young G. P., Cole S. R. et al. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer: 2006; 107 2152 2159 (Pubitemid 44665648)
112. St John D. J., Young G. P., Alexeyeff M. A. et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology: 1993; 104 1661 1668 (Pubitemid 23235456)
113. Starkey B. J. Screening for colorectal cancer. Ann Clin Biochem: 2002; 39 351 365 (Pubitemid 34743637)
114. Steele R. JC, Pox C., Kuipers E. J. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Managment of lesions detected in colorectal cancer screening. Endoscopy: 2012; 44 SE140 SE150
115. Steele R. JC, Rey J-F, Lambert R. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Professional requirements and training. Endoscopy: 2012; 44 SE106 SE115
116. Syed A. A., Khatoon B. A., Silwadi M. F. New reagents for detection of faecal occult blood. J Pharm Biomed Anal: 2001; 24 581 586 (Pubitemid 32119573)
117. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. BMJ: 2004; 329 133
118. Valori R., Rey J-F, Atkin W. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First edition. Quality assurance in endoscopy in colorectal screening and diagnosis. Endoscopy: 2012; 44 SE88 SE105
119. van Roon A. HC, Wilschut J. A., van Ballegooijen M. et al. Attendance and diagnostic yield of 1 vs 2-sample fecal immunochemical test (FIT) screening: a comparative population-based colorectal cancer trial. Oral Presentation, Diagnostic Diseases Week 2010, New Orleans.: 2010
120. van Rossum L. G., van Rijn A. F., Laheij R. J. et al. Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer: 2009; 101 1274 1281
121. van Rossum L. G., van Rijn A. F., Laheij R. J. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology: 2008; 135 82 90 (Pubitemid 351899018)
122. Vilkin A., Rozen P., Levi Z. et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol: 2005; 100 2519 2525
123. von Karsa L., Anttila A., Ronco G. et al. Cancer Screening in the European Union. Report on the implementation of the Council Recommendation on Cancer Screening First Report. Luxembourg European Commission: 2008; http://ec.europa.eu/health/archive/ph-determinants/genetics/documents/ cancer-screening.pdf Accessed 11/2/2012
124. von Karsa L., Lignini T. A., Patnick J. et al. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol: 2010; 24 381 396
125. von Roon A. C., Karamountzos L., Purkayastha S. et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol: 2007; 102 803 813 (Pubitemid 46496634)
126. Wang D. R., Tang D. Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol: 2008; 14 524 531 (Pubitemid 351320817)
127. Welch C. L., Young D. S. Spectrophotometry of occult blood in feces. Clin Chem: 1983; 29 2022 2025 (Pubitemid 14203603)
128. Wilson J. M., Jungner Y. G. Principles and practice of mass screening for disease. World Health Organization: 1968; http://whqlibdoc.who.int/php/WHO-PHP- 34.pdf Accessed 11/2/2012
129. Wong B. C., Wong W. M., Cheung K. L. et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther: 2003; 18 941 946 (Pubitemid 37346679)
130. Young G. P., Cole S. New stool screening tests for colorectal cancer. Digestion: 2007; 76 26 33 (Pubitemid 47608857)
131. Young G. P., Sinatra M. A., St John D. J. Influence of delay in stool sampling on fecal occult blood test sensitivity. Clin Chem: 1996; 42 1107 1108 (Pubitemid 26231420)
132. Young G. P., St John D. J., Cole S. R. et al. Prescreening evaluation of a brush-based faecal immunochemical test for haemoglobin. J Med Screen: 2003; 10 123 128 (Pubitemid 38296847)
133. Young G. P., St John D. J., Winawer S. J. et al. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol: 2002; 97 2499 2507
134. Zappa M., Castiglione G., Paci E. et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the District of Florence experience. Int J Cancer: 2001; 92 151 154 (Pubitemid 32187045)
135. Zappa M., Visioli C. B., Ciatto S. et al. Gastric cancer after positive screening faecal occult blood testing and negative assessment. Dig Liver Dis: 2007; 39 321 326 (Pubitemid 46432240)
136. Zhou L., Yu H., Zheng S. [The value of "occult blood bead" in detection of upper digestive tract disorders with bleeding]. Zhonghua Zhong Liu Za Zhi: 1999; 21 48 50
137. Zorzi M., Falcini F., Fedato C. et al. Screening for colorectal cancer in Italy: 2006 survey. Epidemiol Prev: 2008; 32 55 68